Publication | Closed Access

An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy

InflammationAutoimmune DiseaseAllergyT-regulatory CellImmunologyImmune RegulationRegulatory T CellsImmunologic MechanismAutoimmunityT Cell ImmunityOral AdministrationImmunotherapyMedicine